加味附子理中汤联合表皮生长因子受体-酪氨酸激酶抑制剂治疗非小细胞肺癌的疗效观察  

Clinical observation of modified Fuzi Lizhong decoction combined with epidermal growth factor receptor-tyrosine kinase inhibitor in the treatment of non-small cell lung cancer

作　　者：张万海 何宏涛 毛跃峰 ZHANG Wanhai;HE Hongtao;MAO Yuefeng(Department of Oncology,Pingdingshan The Second People’s Hospital,Pingdingshan 467000,He’nan,China)

机构地区：[1]平顶山市第二人民医院肿瘤科,河南平顶山467000

出　　处：《癌症进展》2020年第22期2330-2332,2351,共4页Oncology Progress

摘　　要：目的探讨加味附子理中汤联合表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)治疗非小细胞肺癌(NSCLC)的疗效。方法根据治疗方法的不同将86例NSCLC患者分为观察组和对照组,各43例。对照组患者接受EGFR-TKI治疗,观察组患者接受加味附子理中汤联合EGFR-TKI治疗。比较两组患者治疗后的近期疗效、卡氏功能状态(KPS)评分、中医证候积分、生存情况和药物不良反应发生情况。结果观察组患者的总有效率为72.09%(31/43),高于对照组患者的48.84%(21/43)(P﹤0.05)。治疗后,观察组患者的KPS评分明显高于对照组患者(P﹤0.01)。治疗后,观察组患者咳嗽、痰中带血、胸闷气促和神疲乏力的积分均明显低于对照组患者(P﹤0.01)。治疗后,观察组患者的3年、5年生存率均高于对照组患者(P﹤0.05)。两组患者腹泻的发生率比较,差异有统计学意义(P﹤0.01)。结论加味附子理中汤联合EGFR-TKI治疗能够有效提高NSCLC患者的生活质量,改善患者的中医证候及生存情况,临床应用价值较高。Objective To explore the curative effect of modified Fuzi Lizhong decoction combined with epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)on non-small cell lung cancer(NSCLC).Method According to different treatment methods,86 patients with NSCLC were divided into observation group and control group,with 43 patients in each group.The patients in the control group were treated with EGFR-TKI,and the patients in the observation group were treated with modified Fuzi Lizhong decoction combined with EGFR-TKI.The short-term efficacy,Karnofsky performance status(KPS)score,traditional Chinese medicine syndrome score and the survival rate,as well as adverse drug reactions were compared between the two groups.Result The total effective rate of the observation group was 72.09%(31/43),which was significantly higher than that of the control group(48.84%,21/43)(P<0.05).After treatment,the score of KPS in the observation group was significantly higher than that in the control group(P<0.01).After treatment,the scores of cough,blood in phlegm,chest tightness,shortness of breath and fatigue in the observation group were significantly lower than those in the control group,and the differences were statistically significant(P<0.01).The 3-and 5-year survival rates in the observation group were significantly higher than those in the control group(P<0.05).The incidence of diarrhea between the two groups was statistically significant(P<0.01).Conclusion Modified Fuzi Lizhong decoction combined with EGFR-TKI can effectively improve the quality of life of NSCLC patients,improve their traditional Chinese medicine syndromes and their living conditions,with higher clinical application value.

关 键 词：加味附子理中汤 表皮生长因子受体-酪氨酸激酶抑制剂 非小细胞肺癌 疗效 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]